IP Library Granted Patent US 7,794,747
Granted Patent B2
US 7,794,747 · App. 11/018,574 · Granted Sep 14, 2010

Method of producing a cationic liposomal preparation comprising a lipophilic compound

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,794,747
App. No.
11/018,574
Granted
Sep 14, 2010
Kind
B2
Abstract

A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.

Claims (28)

1. A method for producing a cationic liposomal preparation comprising:

(a) mixing an organic solvent with a taxane and a cationic lipid to form an organic solution;

(b) mixing the organic solution of step (a) with an aqueous solution comprising a stabilizing agent to form a dispersion of cationic liposomes, wherein the dispersion comprises cationic liposomes in an aqueous medium and wherein the pH value of the aqueous medium is between 3 and 7;

(c) homogenising the dispersion of step (b) at least once;

(d) sterile filtrating the dispersion obtained in step (c); and,

(e) dehydrating the dispersion of cationic liposomes of step (d) to form a cationic liposomal preparation;

wherein the cationic liposomes in the dispersion of step (b) comprise at least one cationic lipid in an amount of at least about 30 mol % and a taxane in an amount of at least about 2 mol %; and wherein the stabilizing agent in the dispersion of step (b) is present in an amount of about 0.1% (m/v) to about 20% (m/v).

2. The method of claim 1 , wherein the method further comprises mixing an amphiphile with the organic solvent in step (a).

3. The method of claim 1 , further comprises reconstituting the cationic liposomal preparation of step (e) in an aqueous solution.

4. The method of claim 1 , wherein the method further comprises ultrafiltrating the dispersion before step (c) and/or (d).

5. The method of claim 1 , wherein at least one of the steps (b) to (d) is performed at a temperature between about −1° C. and about 15° C., between about 1° C. and about 10° C., or between about 2° C. and about 8° C.

6. The method of claim 2 , wherein the further amphiphile is non-cationic.

7. The method of claim 1 , wherein the liposomal preparation comprising the taxane is physically and chemically stable in any one of the steps b) to d) for at least about 12 hours at about 2 to about 8° C. and at least about 4 hours at ambient temperature.

8. The method of claim 1 , wherein the taxane is paclitaxel, docetaxel, or any lipophilic derivative thereof.

9. The method of claim 8 , wherein the liposomal preparation comprises paclitaxel in an amount of about 2 mol % to about 5 mol %.

10. The method of claim 8 , wherein the liposomal preparation comprises docetaxel in an amount of at least about 5 mol %.

11. The method of claim 1 , wherein the liposomal preparation comprises liposomes with an average particle size of about 50 nm to about 400 nm or about 100 nm to about 300 nm.

12. The method of claim 6 , wherein the non-cationic amphiphile is a sterol, a phospholipid, a lysolipid, a lysophospholipid, a sphingolipid, a pegylated lipid or a combination thereof.

13. The method of claim 12 , wherein the sterol is cholesterol.

14. The method of claim 12 , wherein the phospholipid is diacylphosphatidylcholine.

15. The method of claim 1 , wherein the pH value of the aqueous medium in step (b) is between 4 and 6.5 or between 4.5 and 5.5.

16. The method of claim 1 , wherein the cationic liposomal preparation comprises a non-volatile organic acid.

17. The method of claim 16 , wherein the non-volatile organic acid is citric acid.

18. The method of claim 3 , wherein reconstitution of the cationic liposomal preparation is performed at a temperature between about −1° C. and about 15° C., between about 1° C. and about 10° C., or between about 2° C. and about 8° C.

19. The method of claim 3 , wherein the liposomal preparation comprising the taxane is physically and chemically stable for at least about 12 hours at about 2 to about 8° C. and at least about 4 hours at ambient temperature.

20. The method of claim 1 , wherein step (c) is performed by filtration through membrane filters, high pressure homogenisation and/or high speed homogenization, or extrusion through a membrane with a defined pore size under pressure.

21. The method of claim 20 , wherein the pore size of the membrane is about 200 nm.

22. The method of claim 15 , wherein the pH value of the aqueous medium is step (b) is between 4.0 and 6.0.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2016
From: MEDIGENE AG
To: SYNCORE BIOTECHNOLOGY CO., LTD
Reel/Frame 037868/0317 →
MERGER Recorded May 8, 2006
From: MEDIGENE ONCOLOGY GMBH
To: MEDIGENE AG
Reel/Frame 017594/0776 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2005
From: MUNDUS, CARSTEN; WELZ, CHRISTIAN; SCHRAMEL, OLIVER; HAAS, HEINRICH; FICHERT, THOMAS; SCHULZE, BRITA; PEYMANN, TORALF; MICHAELS, UWE; TEIFEL, MICHAEL; GRUBER, FRIEDRICH; WINTER, GERHARD
To: MEDIGENE ONCOLOGY GMBH
Reel/Frame 016605/0983 →
PURCHASE AGREEMENT Recorded May 27, 2005
From: MUNICH BIOTECH AG
To: MEDIGENE ONCOLOGY GMBH
Reel/Frame 016615/0700 →